Owlet (OWLT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
5 Mar, 2026Executive summary
Achieved record FY2025 revenue of $105.7 million, gross margin of 50.6%, and adjusted EBITDA of $2.0 million, marking the strongest year in company history and setting a foundation for continued growth in 2026.
Surpassed 110,000 paying subscribers for the Owlet360 subscription service, with strong sequential growth in MRR, attach rate, and retention, and expanded internationally with new regulatory clearances in India and Israel.
Launched the AI-enabled Dream Sight camera and expanded the product suite, including the Owlet360 subscription service, and announced a strategic AI partnership to enhance pediatric health data insights.
Strengthened capital structure and balance sheet through a warrant exchange and $34.5 million equity offering, supporting cash flow independence and growth investments.
Transitioned into a comprehensive pediatric health, safety, and sleep platform, leveraging AI-enabled products and a growing data ecosystem.
Financial highlights
FY2025 revenue reached $105.7 million, up 35.4% year-over-year; Q4 2025 revenue was $26.6 million, up 29.6%.
FY2025 gross profit was $53.5 million with a record 50.6% gross margin; Q4 gross margin was 47.6%, impacted by tariffs.
FY2025 adjusted EBITDA was $2.0 million, a $3.8 million improvement over FY2024; Q4 adjusted EBITDA was $0.1 million.
FY2025 operating loss improved to $8.3 million from $20.2 million; net loss was $39.7 million, including a $26.6 million non-cash warrant liability adjustment.
Cash and cash equivalents at year-end were $35.5 million, with total liquidity of $45.5 million.
Outlook and guidance
FY2026 revenue guidance is $126–$130 million (19–23% growth), gross margin 49–52%, adjusted EBITDA $3–$5 million (50–150% growth).
Q1 2026 revenue expected at $20–$21 million, gross margin 50–52%, adjusted EBITDA -$2.5 to -$1.5 million.
Guidance includes continued tariff impacts and assumes no material contribution from new countries or telehealth, which are considered upside.
Latest events from Owlet
- Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Proposes up to $100M in securities offerings to fund digital infant health solutions amid key risks.OWLT
Registration Filing16 Dec 2025 - Resale registration for 750,000 shares tied to a term loan, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025 - Registration enables major investors to resell 5.3M shares, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025